Tanvex BioPharma Forging Strategic Alliance with Bora Pharmaceuticals

Combining Tanvex's biosimilar development expertise and U.S. FDA-licensed commercial-scale facility in San Diego, California, with Bora's extensive global CDMO capabilities, the alliance aims to provide comprehensive solutions to biologics CDMO customers around the world.

Tanvex BioPharma recently announced the approval of the acquisition of Bora Biologics Co., Ltd. This merger will unify Bora's CDMO capabilities with Tanvex's development expertise and commercial capacity in San Diego. Bora's Chairman and CEO, Bobby Sheng, will become Chairman of the new organization upon completion in Q1 2025.

Bora Pharmaceuticals operates 10 advanced manufacturing facilities globally and will merge its capabilities with Tanvex's significant biomanufacturing space and scalable services. The combined strengths will cater to the growing demands of biologics CDMO customers.

Henry Chen, CEO of Tanvex, emphasized that this alliance combines resources to offer an integrated suite of services from pre-clinical development to CGMP manufacturing. Bobby Sheng noted that the collaboration aligns with both companies’ vision to address the evolving industry demands and capitalize on new opportunities.